Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 10/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.32 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158658 | 0.95 | ITGA4 (0.41) | ITGA4ITGB1RORCABL1LMNA | |
| SCHEMBL5161598 | 0.88 | ITGA4 (0.40) | ITGA4ITGB1RORCLMNASSTR5 | |
| SCHEMBL5428419 | 0.87 | ITGA4 (0.49) | ITGA4ITGB1RORCLMNA | |
| SCHEMBL5158670 | 0.83 | ITGA4 (0.43) | ITGA4ITGB1RORCLMNAALK | |
| SCHEMBL5160599 | 0.82 | ITGB1 (0.43) | ITGA4ITGB1 | |
| SCHEMBL5160903 | 0.77 | ITGB1 (0.50) | ITGA4ITGB1 | |
| SCHEMBL5423353 | 0.77 | ITGB1 (0.44) | ITGA4ITGB1 | |
| SCHEMBL5428420 | 0.75 | ITGA4 (0.51) | ITGA4ITGB1RORCLMNA | |
| SCHEMBL14371878 | 0.74 | ITGA4 (0.43) | ITGA4ITGB1ABL1LMNASSTR5 | |
| SCHEMBL14608783 | 0.74 | ITGA4 (0.48) | ITGA4ITGB1LMNASSTR5HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 9/4885RORC 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.